Choong Ang Vaccine Laboratory Co., Ltd. Overview
CAVAC is a 58-year-old, family-controlled Korean veterinary biologics specialist. It develops, manufactures and sells vaccines for swine, poultry, dogs, cats, cattle and, from 2027, goats. The company is one of the few Korean-owned firms with an integrated R&D-to-GMP vaccine platform in a domestic market that multinationals (Boehringer Ingelheim, Zoetis, MSD, Ceva and others) have historically dominated with a share of more than 70%. Its franchise brands are SuiShot (swine), FowlShot (poultry), CaniShot and FeliShot (companion animals) and BoviShot (cattle). Revenue was KRW 49.1 bn in FY2025 with an operating margin of about 13%, and the balance sheet holds net cash of about KRW 17 bn. The company has three equity-story pillars. The first is a steady domestic livestock-vaccine business, part of it sold through government procurement. The second is a growing export channel covering 20+ countries, with first-of-kind Korean entries into China and Brazil for Suishot Circo-ONE. The third is optionality from an export-licensed live attenuated African swine fever (ASF) vaccine, SuiShot ASF-X, which is awaiting registration in Vietnam and the Philippines.
What the company does
CAVAC manufactures and sells biological preparations, mainly vaccines, that prevent infectious disease in production animals and companion animals. The company describes itself as a leading developer of animal biological medicines. Its self-description emphasises long accumulated expertise and a range of manufacturing technologies, including toxoid, subunit and recombinant vaccines. Its stated flagship disease areas are classical swine fever, porcine epidemic diarrhoea (PED), highly pathogenic porcine reproductive and respiratory syndrome (HP-PRRS) and low-pathogenic avian influenza (LPAI). The company is also developing user-friendly delivery formats, including needle-free, drinking-water, oral and spray administration (company overview as summarised by ValueLine from the business report).
Business and revenue model
The revenue model is almost entirely product sales: finished vaccine vials or doses sold per batch after national lot-release approval from the Animal and Plant Quarantine Agency (APQA). Three secondary streams sit alongside it:
-
Contracted services (용역): contract research, disease testing and biologics studies. About 4% of revenue in Q2 2026 (Butler, citing the business report product mix).
-
Government procurement and distribution: supply under Public Procurement Service (PPS) tenders. This includes vaccines CAVAC makes and, since 2026, vaccines it imports and distributes. An example is a KRW 5.81 bn SAT1 foot-and-mouth disease (FMD) vaccine contract signed 8 July 2026. CAVAC said it would import that volume from overseas manufacturers (Edaily, 8–9 July 2026).
-
Licensing and distribution partnerships abroad: for example, an exclusive distribution agreement under which Elanco China sells Suishot Circo-ONE. The contract terms are not publicly disclosed.
CAVAC has no subscription or royalty income of any significance that has been disclosed.
Sales channels
The most recent channel split found is from the 2019 NICE technology analysis report, using FY2018 data. That year, sales through dealers and agents were 44.2% of revenue, government supply through the PPS was 26.3%, and exports were 27.2%. Management has stated a long-term ambition to raise exports to 60% of revenue (BioBook Media, August 2026).
Customers and end-markets
| End-market | Customer type | Notes |
|---|---|---|
| Swine production (Korea and export) | Integrated pig producers, farm veterinarians, dealers; overseas distributors (Elanco China; partners in Brazil, Thailand, Vietnam) | Largest product family; about 50% of Q2 2026 revenue |
| Poultry (broilers, layers, breeders) | Integrators (for example Harim, a development partner), hatcheries, layer farms | About 28% of Q2 2026 revenue |
| Companion animals (dogs, cats) | Veterinary clinics via distributors | About 11% of Q2 2026 revenue |
| Cattle and small ruminants | Beef and dairy farms; goat farms from 2027 | Cattle about 4% of Q2 2026 revenue |
| Government animal-disease control | MAFRA via PPS | Emergency and stockpile tenders, such as SAT1 FMD in 2026 |
| Contract services | Government, academia, industry | About 4% |
Value-chain position
CAVAC is vertically integrated across seed-strain development, antigen production (cell culture and bioreactors), formulation (including its proprietary adjuvant CAvant), filling, freeze-drying, labelling and quality control under KVGMP. Production takes place at Plant 1 in Daejeon and at Plant 2 in Nonsan, which handles poultry vaccines and animal testing. For live ASF virus, Korean rules require BL3 containment. CAVAC has no such facility, so its ASF vaccine was licensed on a contract-manufacturing basis at a GMP site in Hanoi, Vietnam (DailyVet, April 2026).
Independent characterisation
CAVAC is best understood as a niche, cash-generative biologics manufacturer with embedded R&D optionality. Its core domestic business grows in the mid-single digits and is exposed to livestock cycles and disease outbreaks. It is profitable (operating margin 11–17% over FY2021–FY2025), heavily capitalised relative to revenue (equity of KRW 105 bn against revenue of KRW 49 bn) and conservatively financed. Inventory intensity is a structural feature of vaccine manufacturing: work-in-progress and semi-finished antigen are held for long periods. Inventory reached KRW 22.0 bn at end-FY2025, or about 45% of annual revenue. The market values CAVAC below book value (P/B about 0.77×), which suggests investors are not paying for the ASF or FMD options.
Strategy
Stated strategic themes
Company materials and the business report emphasise the following themes, paraphrased:
Vision: to be a "Global Bio Leader" that pursues animal health and human well-being (company deck).
Global network: expand exports through a worldwide distribution network, and win more overseas product registrations by strengthening GMP standards.
R&D-led portfolio renewal: bring vaccines matched to locally circulating strains to market quickly, such as Y280 LPAI, the PED G2b variant and Korean swine influenza subtypes.
User convenience: develop needle-free, water-delivered, oral and spray administration.
Government partnership: take part in national disease-control programmes and procurement.
Initiatives announced in the last 24 months
| Date | Initiative | Description and strategic intent |
|---|---|---|
| 6 Aug 2025 | Harim poultry-disease MOU | Harim monitors respiratory disease on its contract farms and supplies IB field isolates and data; CAVAC develops variant-matched IB vaccines |
| Sep 2025 | ASF bait vaccine research in Vietnam | Extends the ASF platform to wild boar, an area of European interest |
| Oct–Dec 2025 | Shareholder-return programme | KRW 1.0 bn buyback (decided 30 Oct 2025; 101,906 shares bought between 3 Nov 2025 and 30 Jan 2026, 97.7% of the plan); KRW 2.0 bn treasury-share cancellation (10 Dec 2025) |
| Feb 2026 | FowlShot ND Max launch | Large-pack product for large broiler integrators |
| 25 Feb 2026 | ASF vaccine results presentation | Targets commercialisation in 2027; calls for a national expert consultative body on ASF vaccine use in Korea |
| 25 Mar 2026 | Corporate value-up plan disclosure | Discloses "high-dividend company" status under the Restriction of Special Taxation Act, so eligible shareholders can opt for separate dividend taxation. |
| 15 Apr 2026 | SuiShot ASF-X export licence | Path to registration and sales in Vietnam and the Philippines |
| Apr 2026 | K-FMD clinical trial with Optipharm | Domestic FMD vaccine sovereignty and non-BL3 manufacturing |
| Jun 2026 | IPVS 2026 satellite symposium | International positioning of ASF-X |
| 25 Jun 2026 | CapriShot CLA licence; KRW 2.1 bn share cancellation | Enters the goat segment, in line with MAFRA's February 2026 Goat Industry Development Plan |
| 8 Jul 2026 | SAT1 FMD vaccine supply to PPS | Builds the procurement and distribution business; CAVAC says it will expand vaccine supply work as disease-control needs change |
| Undated (2025–26) | Daejeon companion-animal industry agreement | Agreement with Daejeon City, Chungnam National University and O-World to grow the local pet industry |
Medium-term targets and guidance
| Target | Timing | Source |
|---|---|---|
| Raise exports to 60% of revenue | No date | BioBook Media (Aug 2026) |
| Commercialise the ASF vaccine (Vietnam and the Philippines first) | 2,027 | DailyVet (Feb 2026) |
| K-FMD product licence and launch | Licence 2026; launch 2027 | DailyVet (Apr 2026) |
| CapriShot CLA launch | H1 2027 | DailyVet (Jul 2026) |
CAVAC gives no formal financial guidance. The following non-financial targets have been disclosed:
ESG commitments and cost-reduction programmes with quantified targets are not publicly disclosed.
Products & Services
Portfolio size is reported differently across years: "over 80 products" (DailyVet, 2020–2021), "about 70 products" (eToday, 2023) and an export lineup of "85+ products" (BioBook Media, 2026). The differences probably reflect whether product counts, registrations or SKUs are being counted. Pricing is not publicly disclosed for any product. Livestock vaccines are generally sold per vial or per dose through dealers or tenders.
Swine — SuiShot® brand
| Product | Description and capabilities | Target customer | Launch / status | Notes |
|---|---|---|---|---|
| SuiShot® Circo-ONE | Porcine circovirus type 2 (PCV2) vaccine preventing PCV-associated disease (PCVAD) | Pig farms in Korea, China, Brazil and elsewhere | Registered in China Oct 2023 (first Korean animal vaccine there); Brazil shipments from Apr 2024; China shipments from Oct 2024 | Distributed in China by Elanco China under an exclusive agreement |
| SuiShot® PED-X | Inactivated vaccine against the G2b variant of PED virus, which spread across Korea from 2014 | Breeding herds (sows) | 2015; described as Korea's first G2b inactivated vaccine | Described as a top PED product and a leading export earner (eToday 2023) |
| SuiShot® PED-X Live | Oral live second-generation PED vaccine; the company called it a world first | Breeding herds | Highlighted at the 2020 IHS Markit award | — |
| SuiShot® CSFV Marker-L | Classical swine fever live marker vaccine (supports differentiating infected from vaccinated animals) | Pig farms | Highlighted 2020 | — |
| SuiShot® Flu-3 | Trivalent swine influenza vaccine covering the Korean field subtypes H1N1, H1N2 and H3N2 | Pig farms | Promoted at the 2025 "SuiShot Re:Booster Day" seminar | Positioned for locally circulating strains |
| SuiShot® ASF-X | Live attenuated ASF vaccine based on strain ASFV-MEC-01, isolated from a Korean wild boar and attenuated. Genotype II protection. Labelled for sows, gilts and piglets (two intramuscular doses given three weeks apart) | ASF-endemic markets (Vietnam, Philippines first) | Export-only licence 15 Apr 2026; registration under way in Vietnam and the Philippines; commercialisation target 2027 | Contract-manufactured in Hanoi. The company says it is the first commercial ASF vaccine with sow and gilt claims |
| HP-PRRS vaccine | Vaccine against highly pathogenic PRRS | Pig farms | Listed as a flagship area in the company overview | — |
| ASF oral bait vaccine (pipeline) | Oral bait formulation for wild boar | Wildlife authorities (European interest noted) | Research in Vietnam (DailyVet, Sep 2025) | Pre-commercial |
Poultry — FowlShot® brand
| Product | Description and capabilities | Target customer | Launch / status | Notes |
|---|---|---|---|---|
| FowlShot® Flu-Y280 | Inactivated LPAI H9N2 vaccine using the Y280-lineage strain that APQA developed from a 2021 Hwasun isolate and transferred to industry | Layers, breeders, broilers | Early 2023; first Y280 vaccine on the market | Addresses Y280 strains against which older Y439 vaccines gave poor protection |
| FowlShot® 5280 ABBNE | Five-way inactivated combination: Y280 LPAI + two nephropathogenic IB strains (QX and KM91) + Newcastle disease (ND) + egg drop syndrome (EDS); uses the CAvant® adjuvant | Layers and breeders | National lot release 19 Oct 2023 | Reduces the number of injections per flock |
| FowlShot® 4280 ABBN | Four-way combination: Y280 LPAI + IB (QX, KM91) + ND; CAvant® adjuvant | Layers and breeders | Launched 1 Feb 2024 | Line extension |
| FowlShot® Adeno trivalent | Trivalent vaccine against fowl adenovirus serotypes 4, 8b and 11 | Broiler breeders | Developed Apr 2023; launch seminar 26 Jul 2023 | Responds to limited cross-protection between serotypes |
| FowlShot® ND Max | Large-pack (5,000-dose) enterotropic ND live vaccine | Large broiler operations | Launched Feb 2026 | Enterotropic strain designed for short respiratory persistence |
| FowlShot® IB range | IB vaccines positioned against the emerging K-IId QX-type IB virus | Poultry integrators | Trade-press feature Jul 2026 | A Harim co-development pipeline (2025 MOU) targets variant IB strains |
| Earlier AI vaccine | Avian influenza vaccine | Poultry | Developed Dec 2006, sold from Feb 2007 | Historical |
Companion animals
| Product line | Description | Target customer | Status |
|---|---|---|---|
| CaniShot® | Canine vaccines | Veterinary clinics | Active; about 11% of revenue in Q2 2026 |
| FeliShot® | Feline vaccines | Veterinary clinics | Active; share not separately disclosed |
Ruminants and other species
| Product line | Description | Target customer | Status |
|---|---|---|---|
| BoviShot® | Cattle vaccines | Beef and dairy farms | Active; about 4% of revenue |
| CapriShot® Caseous Lymphadenitis | Inactivated vaccine against Corynebacterium pseudotuberculosis combining whole-cell bacterin and toxoid; Korea's first licensed CLA vaccine for goats | Goat farms | Licensed 25 Jun 2026; launch planned for H1 2027 |
| Fish and rabbit vaccines | Mentioned in the company's English profile | Aquaculture, rabbit producers | — |
Platforms, technology and services
| Offering | Description |
|---|---|
| CAvant® adjuvant | Proprietary immune-enhancing adjuvant used in FowlShot combination vaccines |
| Manufacturing technology base | Toxoid, subunit and recombinant vaccine manufacturing; bioreactors; freeze-drying; automated vial filling and packaging (KVGMP) |
| Contract services | Biologics research and disease testing services (about 4% of revenue) |
| Import and distribution | SAT1 FMD vaccine imported and supplied to the government under the July 2026 PPS contract |
| K-FMD vaccine (pipeline) | Nanoparticle-based FMD vaccine. Optipharm developed the master seed and CAVAC produces the clinical-trial material. The vaccine can be made in a standard (non-BL3) facility. Six-month field trial on six cattle and pig farms; target of licensing in 2026 and launch in 2027 (DailyVet, Apr 2026) |
Financial Narrative
All figures are K-IFRS standalone, KRW bn unless stated. Main sources are DART business reports as aggregated by ETF Shopping and Butler (revenue, operating income, net income for FY2021–FY2025), the FY2024 AGM results filing, and ValueLine (detailed line items for the balance sheet FY2022–FY2025, and income-statement and cash-flow detail for FY2025). Some aggregator figures differ slightly from audited figures because of rounding. For example, FY2024 operating income is 5.8 in the aggregators against 5.758 in the AGM filing.
Income statement
Margins are derived. FY2024 operating and net income come from the 25 Mar 2025 AGM filing (KRW 5,758m and KRW 6,850m). FY2025 operating and net income come from ValueLine line items (KRW 6.47 bn and KRW 6.15 bn). Kormedi, citing the year-end disclosure, rounds these to KRW 6.5 bn and KRW 6.2 bn.
Revenue CAGR for FY2021–FY2025 was 4.7%. For FY2023–FY2025 it was 8.3%. Both are derived. BioBook Media separately reports that the company described growth of 8% or more a year over 2023–2025.
FY2025 detailed income statement (ValueLine, standalone):
Diluted EPS equals basic EPS because no dilutive instruments are disclosed.
EPS (basic, KRW):
The FY2024 figure comes from the AGM filing and the FY2025 figure from ValueLine.
Commentary. Revenue fell in FY2022 (-3.9%), the only decline in the window. It then grew for three consecutive years, driven by new poultry products (the Y280 LPAI combinations from 2023), PCV2 export entries (Brazil and China from 2024) and price and mix. Operating margin peaked at 16.7% in FY2023. It fell to 12.6% in FY2024 as payroll costs rose: average pay jumped from KRW 38.3m to KRW 51.0m per head, and payroll intensity went from 16.3% to 20.9% of revenue (ETF Shopping). FY2025 brought partial recovery to 13.2%. Net income has run above operating income in most years. Interest income on a sizeable cash and deposit pile and foreign-exchange gains on export receivables explain the gap.
Interim and trailing results
Q3 2025 comes from Edaily (Nov 2025). Q2 2026 comes from Kormedi, citing the preliminary results disclosure of 5 Aug 2026. Q1 2026 is derived as H1 2026 minus Q2 2026.
H1 2026 revenue was down 3.1% year on year, while operating income rose 9.3% and net income 65.6% (Kormedi, citing the disclosure). In Q2 2026, revenue fell 1.2% and operating income fell 23.8% year on year, yet net income rose 90.4%. BioBook Media attributes the gap mainly to non-operating gains, including foreign-exchange gains on export business.
On a trailing twelve-month basis to June 2026 (ValueLine), revenue was KRW 48.27 bn, operating income KRW 6.83 bn, EBITDA KRW 14.60 bn and net income KRW 7.98 bn (EPS KRW 838).
Balance sheet
Total borrowings, net debt and working capital are derived. Net debt is borrowings minus cash and short-term financial instruments; lease liabilities (about KRW 0.1–0.3 bn) are excluded. Working capital is current assets minus current liabilities.
At 30 June 2026, total assets were KRW 125.51 bn, inventories KRW 24.99 bn, cash plus short-term instruments KRW 26.93 bn, borrowings KRW 6.17 bn and equity KRW 108.11 bn (BPS KRW 11,430).
Commentary. The balance sheet has de-risked steadily. Short-term borrowings of KRW 6.4 bn at end-FY2022 were repaid, total borrowings fell by 44% between FY2022 and FY2025, and net cash grew from KRW 3.6 bn to KRW 17.2 bn. PP&E stays near KRW 63–67 bn, reflecting the Nonsan Plant 2 investment completed around 2021, and it makes up about half of total assets. This is a capital-heavy footprint for a KRW 49 bn revenue base, and it holds down asset turnover. The clearest recent change is inventory, which rose 24% in FY2025 to KRW 22.0 bn and then to KRW 25.0 bn by June 2026. In FY2024 semi-finished goods (KRW 9.5 bn at FY2025) were reclassified out of work-in-progress, so movements within inventory categories need care. Plausible drivers include stock-building for export launches and longer production cycles; the SAT1 FMD imports, which began in July 2026, could explain only the post-June build.
Cash flow
Source: ValueLine, FY2025 column. The aggregator's free-cash-flow definition is narrower than OCF minus PP&E capex.
On a trailing twelve-month basis to June 2026, operating cash flow was KRW 11.37 bn, PP&E capex KRW 5.60 bn and free cash flow (ValueLine definition) KRW 3.69 bn.
Shareholder cash returns, FY2021–FY2025 (ETF Shopping from DART; buybacks on a cash-flow-statement purchase basis):
Commentary. FY2025 operating cash flow (KRW 7.9 bn) was below FY2025 EBITDA (KRW 12.5 bn). About KRW 5.9 bn was absorbed by working capital, mostly inventory (KRW -4.2 bn), along with severance and pension payments. With capex of about KRW 5.9 bn, near maintenance level against KRW 6.2 bn of depreciation, free cash flow was roughly breakeven. Even so, the company paid out KRW 4.9 bn in dividends and buybacks and repaid debt, drawing on its deposits. Cash generation improved in H1 2026 (TTM OCF KRW 11.4 bn) as receivables were collected.
Ratios
All ratios are derived from the figures above.
ValueLine reports a five-year average ROE of 6.10% and a TTM ROE of 7.39%.
Commentary. Returns are modest: ROE of 6–7% sits well below Korea's typical cost of equity. The reason is not weak margins but excess capital: KRW 24 bn of cash and deposits against KRW 105 bn of equity, plus low asset turnover. The cash conversion cycle of nearly a year is structurally long. Vaccine antigen and semi-finished goods carry long QC and lot-release lead times, and the business pays suppliers quickly. Inventory discipline is therefore the most important operating lever for cash generation. Leverage risk is negligible.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Product Families
| Product family | Share of revenue, Q2 2026 (%) |
|---|---|
Swine vaccines (SuiShot) | 50 |
Poultry vaccines (FowlShot) | 28 |
Canine vaccines (CaniShot) | 11 |
Services (contract research and testing) | 4 |
Cattle vaccines (BoviShot) | 4 |
Other (feline, other species, merchandise; residual) | 3 |
Investee Details
| Investee | CAVAC stake (%) | Investee total assets (KRW Bn) | Investee net income (KRW Bn) | Nature |
|---|---|---|---|---|
GPI CAVAC Biologicals, LLC | 10 | 2.27 | -0.016 | — |
Avinext Co., Ltd. (㈜아비넥스트) | 12 | 1.45 | 0.15 | ASF vaccine co-developer (ASFV-MEC-01 consortium) |
Hansu Pharm Co., Ltd. (㈜한수약품) | 2 | 1.71 | 0.044 | Veterinary pharmaceutical company run by the Korean Veterinary Medical Association |
Korea Animal Medicine Industrial Cooperative | — | 1.87 | 0.010 | Industry cooperative membership |
“—” = not publicly disclosed.
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 40.9 | 39.3 | 41.9 | 45.6 | 49.1 |
Revenue growth (%) | 12.7 | -3.9 | 6.5 | 8.9 | 7.6 |
Operating income (KRW Bn) | 4.5 | 4.3 | 7.0 | 5.76 | 6.47 |
Net income (KRW Bn) | 7.6 | 4.0 | 6.0 | 6.85 | 6.15 |
Operating margin (%) | 11.0 | 10.9 | 16.7 | 12.6 | 13.2 |
Net margin (%) | 18.6 | 10.2 | 14.3 | 15.0 | 12.5 |
Dividend per share (KRW) | 100 | 100 | 150 | 170 | 200 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Analysis
| Line item (FY2025) | KRW Bn | % of revenue (derived) |
|---|---|---|
Revenue | 49.06 | 100.0 |
Cost of sales | 25.18 | 51.3 |
Gross profit | 23.88 | 48.7 |
SG&A | 17.40 | 35.5 |
of which R&D expense | 2.24 | 4.6 |
of which salaries | 5.98 | 12.2 |
of which fees and commissions | 2.78 | 5.7 |
Operating income | 6.47 | 13.2 |
EBITDA (ValueLine definition) | 12.49 | 25.5 |
Net financial income | 0.20 | 0.4 |
Other non-operating, net | -0.12 | -0.2 |
Pre-tax income | 6.55 | 13.4 |
Income tax | 0.39 | 0.8 |
Net income | 6.15 | 12.5 |
Basic EPS (KRW) | 638 | — |
Per-Share Data
| Metric | FY2024 | FY2025 |
|---|---|---|
Basic EPS (KRW) | 713 | 638 |
Income Statement
| Metric | Q3 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|
Revenue (KRW Bn) | 10.98 | 12.59 | 11.90 |
Operating income (KRW Bn) | 1.55 | 3.00 | 1.14 |
Net income (KRW Bn) | — | 3.33 | 1.29 |
Income Statement (Half-Yearly)
| Metric | H1 2025 | H1 2026 |
|---|---|---|
Revenue (KRW Bn) | 25.29 | 24.50 |
Operating income (KRW Bn) | 3.79 | 4.14 |
Net income (KRW Bn) | 2.79 | 4.62 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Total assets (KRW Bn) | 114.85 | 119.59 | 123.27 | 122.81 |
Current assets (KRW Bn) | 39.59 | 50.56 | 52.45 | 51.61 |
Cash and equivalents (KRW Bn) | 7.84 | 14.38 | 13.46 | 10.47 |
Short-term financial instruments (KRW Bn) | 7.91 | 12.77 | 15.40 | 13.55 |
Trade receivables (KRW Bn) | 3.21 | 4.19 | 4.79 | 4.37 |
Inventories (KRW Bn) | 17.91 | 18.46 | 17.69 | 22.02 |
Property, plant and equipment (KRW Bn) | 66.64 | 62.83 | 64.08 | 63.66 |
Intangible assets (KRW Bn) | 0.43 | 0.53 | 1.06 | 1.08 |
Goodwill (KRW Bn) | 0 | 0 | 0 | 0 |
Current liabilities (KRW Bn) | 13.31 | 12.65 | 12.01 | 12.09 |
Short-term borrowings (KRW Bn) | 6.42 | 0 | 0 | 0 |
Current portion of long-term debt (KRW Bn) | 0 | 4.09 | 1.69 | 2.00 |
Long-term borrowings (KRW Bn) | 5.78 | 6.53 | 6.84 | 4.84 |
Total borrowings (KRW Bn) | 12.20 | 10.62 | 8.53 | 6.84 |
Net debt (KRW Bn; negative = net cash) | -3.55 | -16.53 | -20.33 | -17.18 |
Total liabilities (KRW Bn) | 19.55 | 19.78 | 19.40 | 17.44 |
Shareholders' equity (KRW Bn) | 95.30 | 99.80 | 103.86 | 105.36 |
Working capital (KRW Bn) | 26.28 | 37.91 | 40.44 | 39.52 |
Book value per share (KRW) | 9,569 | 10,333 | 10,754 | 11,140 |
Cash Flow
| Metric | FY2025 |
|---|---|
Operating cash flow (KRW Bn) | 7.87 |
Capital expenditure, PP&E (KRW Bn) | 5.91 |
Capital expenditure, intangibles (KRW Bn) | 0.05 |
Free cash flow, ValueLine definition (KRW Bn) | -0.04 |
Depreciation, PP&E (KRW Bn) | 6.17 |
Dividends paid (KRW Bn) | 1.62 |
Treasury-share purchases (KRW Bn) | 3.00 |
Long-term debt repaid (KRW Bn) | 1.69 |
Dividends & Capital Returns and Returns & Leverage Ratios (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividends declared (KRW Bn) | 1.0 | 1.0 | 1.4 | 1.6 | 1.9 |
Treasury share purchases (KRW Bn) | 1.6 | 1.0 | 0.1 | 1.1 | 3.0 |
Total shareholder return (KRW Bn) | 2.6 | 2.0 | 1.5 | 2.7 | 4.9 |
Dividend payout ratio (%) | 13 | 24 | 24 | 24 | 30 |
Total payout ratio (%) | 34 | 50 | 26 | 39 | 79 |
Margin Analysis (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE, net income / year-end equity (%) | 4.2 | 6.0 | 6.6 | 5.8 |
ROA, net income / year-end assets (%) | 3.5 | 5.0 | 5.6 | 5.0 |
Current ratio (x) | 2.97 | 4.00 | 4.37 | 4.27 |
Debt to equity (%) | 12.8 | 10.6 | 8.2 | 6.5 |
Liabilities to equity (%) | 20.5 | 19.8 | 18.7 | 16.6 |
Asset turnover (x) | 0.34 | 0.35 | 0.37 | 0.40 |
Financial Analysis — ROIC
| Ratio (FY2025) | Value | Basis |
|---|---|---|
ROIC (%) | 6.9 | NOPAT (operating income × (1 – 6% effective tax rate)) ÷ (equity + debt – cash and short-term instruments); derived |
Net debt / EBITDA (x) | -1.4 | Net cash position; derived |
Interest coverage (x) | 30.8 | Operating income ÷ interest expense of KRW 0.21 bn; derived |
EBITDA margin (%) | 25.5 | ValueLine |
Days sales outstanding | 33 | Year-end trade receivables ÷ revenue × 365; derived |
Days inventory outstanding | 319 | Year-end inventory ÷ cost of sales × 365; derived |
Days payables outstanding | 8 | Year-end trade payables (KRW 0.58 bn) ÷ cost of sales × 365; derived |
Cash conversion cycle (days) | about 344 | Derived; year-end balances, not averages |
Revenue by Region (%)
| Metric | FY2016 | FY2018 |
|---|---|---|
Export share of revenue (%) | 13 | 27.2 |
Region Overview
| Region | Disclosed markets | Status and evidence |
|---|---|---|
Southeast Asia | Thailand, Vietnam (named as main export markets, 2023), Philippines, Cambodia, Indonesia, Myanmar | Core export region; site of ASF-X field trials and the registration pipeline |
Greater China | China | Circo-ONE registered Oct 2023; Elanco China exclusive distribution; first shipments Oct 2024 |
Latin America | Brazil (Circo-ONE from Apr 2024), Mexico | Brazil described by the company as a very large new market |
Middle East | Bahrain, UAE, Jordan | Listed export destinations (PR Newswire, 2021) |
South Asia | India, Pakistan | Listed export destinations |
Africa | Nigeria, Egypt | Listed export destinations |
CIS | Russia | Listed export destination (2021) |
Domestic (Korea) | Nationwide via dealers, PPS and veterinary distributors | Largest revenue base |
Share Price and Market Valuation
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Year-end share price (KRW) | 11,000 | 11,010 | 9,800 | 9,800 |
Year-end market capitalisation (KRW Bn) | 109.6 | 109.7 | 94.7 | 94.7 |
Shares outstanding (millions) | 9.96 | 9.66 | 9.66 | 9.46 |
Capital Markets
| Item | Value | Source |
|---|---|---|
Close, 19 Oct 2026 | KRW 9,110 (+1.22% on the day) | ValueLine |
Market capitalisation | About KRW 83.3 bn | ValueLine |
52-week range | KRW 8,560 – 10,350 | StockHub |
6-month change | -8.16% | ValueLine |
Change from end-FY2025 | -7.0% (derived) | — |
Change from end-FY2022 | -17.2% (derived; excludes dividends) | — |
Valuation Multiples
| Multiple | CAVAC current | CAVAC 5-year average |
|---|---|---|
P/E, TTM (x) | 10.43 | 20.47 |
P/B (x) | 0.77 | 1.09 |
EV/EBITDA (x) | 4.28 | 8.16 |
P/S (x) | 1.73 | 2.53 |
Dividend yield (%) | 2.2 | — |
Per-Share Data (FY2016–FY2025)
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Dividend per share (KRW) | 50 | 50 | 50 | 50 | 70 | 100 | 100 | 150 | 170 | 200 |
Analyst Conclusions
Management guidance and consensus
No formal financial guidance and no consensus forecasts exist. In July 2026 management said the SAT1 contract would help FY2026 results. The contract adds up to KRW 5.81 bn of revenue across July–November 2026. Because the product is imported, the margin on this distribution revenue is likely lower than on CAVAC-manufactured vaccines, but the contract's gross margin is not disclosed. Q3 2026 preliminary results are expected in early November 2026, based on the usual timing of the first week of November.
Bull case
-
ASF-X becomes a step-change product. If registrations in Vietnam and the Philippines arrive and the sow and gilt claim holds up, the FY2025 base of about KRW 30 bn in swine-related revenue could be supplemented materially. Even a small share of Southeast Asia's endemic ASF markets would be large relative to KRW 49 bn of total revenue.
-
Valuation already offers downside support. At 0.77× book, 4.3× EV/EBITDA, a 2.2% yield and a 79% FY2025 total payout, investors pay little or nothing for the pipeline. Net cash covers about 25% of market capitalisation.
-
More pipeline shots and domestic tailwinds. K-FMD (licence targeted for 2026) addresses a market where Korea currently imports all its FMD vaccine. The goat CLA launch and Harim IB development add growth, and government support for vaccine sovereignty (BL3 access, procurement) is strengthening.
Bear case
-
The core business is stagnating. H1 2026 revenue fell 3.1% and Q2 operating income fell 23.8%. The jump in net income came from non-operating gains, which are low quality. Payroll intensity is rising.
-
ASF commercial risk is high. CAVAC has no BL3 facility of its own. Komipharm has a parallel licence and BL3 access. Vietnam already has licensed local incumbents. WOAH has publicly voiced caution about live ASF vaccines. Timelines have already moved: the 2025 strain-establishment goal was followed by a 2027 commercialisation target.
-
Capital efficiency and cash conversion are poor. ROE is about 6%, inventory is rising, the cash cycle is about 344 days and FY2025 FCF was about breakeven. Governance is concentrated in the controlling family. Without operating improvement, the discount to book may persist.
Catalysts and monitorables for the next 12 months
| Catalyst / monitorable | Expected timing | What to watch |
|---|---|---|
| Q3 2026 preliminary results | Early Nov 2026 | Revenue contribution from SAT1; operating margin recovery; inventory |
| Completion of SAT1 contract | 7 Nov 2026 | Full recognition of KRW 5.81 bn; follow-on tenders |
| ASF-X registration in Vietnam and/or the Philippines | H2 2026 – 2027 | Approval dates; label claims; manufacturing partner capacity; pricing |
| K-FMD licence decision | Late 2026 – 2027 | Clinical neutralising-antibody results; procurement eligibility |
| FY2026 dividend and buyback decisions | Feb 2027 | Whether DPS rises for a fourth year; payout above 30% |
| CapriShot CLA launch | H1 2027 | Uptake; competition from Woogene B&G |
| Inventory and FCF in FY2026 annual report | Mar 2027 | Reversal of the inventory build |
| Korean policy on domestic ASF vaccine use | Ongoing | Any move from export-only to domestic authorisation |
Analyst verdict
CAVAC is a well-run, conservatively financed niche producer whose share price embeds almost no value for its development pipeline. Over FY2021–FY2025 it compounded revenue at 4.7% a year, kept operating margins in the low-to-mid teens, paid down most of its debt, and doubled its dividend per share while cancelling shares. Those traits explain why the stock trades at 0.77× book and about 4× EV/EBITDA. The market has not rewarded capital that is earning only about 6% returns, held back by surplus cash, a heavy fixed-asset base and inventory that now equals almost half a year's revenue.
The case therefore depends on whether the pipeline turns from licences into revenue. The April 2026 export licence for SuiShot ASF-X is a genuine milestone. Korea became only the second country to license an ASF vaccine, and the sow-and-gilt label differentiates CAVAC's product. Even so, the path to revenue runs through foreign registrations, a Vietnamese contract manufacturer and a competitive field that includes Komipharm, Vietnam's AVAC and Navetco, and multinational entrants. K-FMD and the goat CLA vaccine are credible but smaller options. In the near term the core business needs to show it can grow again: H1 2026 revenue declined, Q2 operating profit contracted sharply, and headline net profit was flattered by currency gains.
On balance, CAVAC fits a patient, value-oriented investor who is comfortable with illiquidity and a controlling family. The downside is cushioned by net cash, a dividend yield above 2% and a payout policy that has improved for three straight years. The upside depends on events: an ASF-X registration in Vietnam or the Philippines would be the clearest re-rating trigger. The main things to watch over the next year are Q3 2026 operating margins, the inventory trajectory, ASF-X registration news and the FY2026 capital-return decision. Absent progress on these, the valuation discount is likely to persist.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure | Background and education | Age / born |
|---|---|---|---|---|
Dr. Yoon In-jung (윤인중) | Chairman and Representative Director | CEO since 1999; re-elected inside director 25 Mar 2025 for 3 years | DVM Konkuk University; MS Veterinary Medicine Seoul National University; PhD Veterinary Medicine University of Minnesota. Son of the founder | Born Aug 1962 (age 64) |
Yoon Seok-in (윤석인) | Representative Director (independent co-representative structure) | — | Related party of the largest shareholder; holds 7.58%. | — |
Dr. Lee Ju-yong (이주용, "Jason Lee") | President; inside director | Formerly Vice President; re-elected inside director 25 Mar 2025 for 3 years | DVM and MS Veterinary Medicine Seoul National University; MBA Maastricht School of Management. Called CEO in international trade press | Born Nov 1973 (age 52) |
Dr. Yoo Sung-sik (유성식) | Head of Overseas Business; head of the ASF project; registered director | — | Presented ASF-X data at IPVS 2026 and at the Feb 2026 results presentation | — |
Founder: Dr. Yoon Ji-byung (윤지병) | Founder (deceased 1999) | 1968–1999 | Seoul National University veterinary graduate (1958); government Animal Health Research Institute | 1934–1999 |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Event |
|---|---|
25 Mar 2025 | Yoon In-jung and Lee Ju-yong re-elected as inside directors |
Major Shareholders
| Holder | Relationship | Stake at 31 Dec 2025 (%) |
|---|---|---|
Yoon In-jung | Largest shareholder | 24.32 |
Yoon Seok-in | Related party | 7.58 |
Kim Eun-hee | Related party | 1.97 |
Yoon Seok-won | Related party | 0.28 |
Kim Pil-bong | Related party | 0.18 |
Lee Han-san | Related party | 0.15 |
Lee Han-cheol | Related party | 0.13 |
Yoon Hee | Related party | 0.13 |
Kim Hyo-jin | Related party | 0.12 |
Lee Han-rim | Related party | 0.11 |
Yoo Sung-sik | Registered officer | 0.01 |
Lee Ju-yong | Registered officer | 0.01 |
Largest shareholder and related parties, total | — | 34.99 |
Minority shareholders (11,071 holders) | — | 58.8 |
Treasury shares (approximate, Butler) | — | 2.13 |
Competitive Landscape
Key Competitors
| Competitor | Type | Overlap with CAVAC | Relative positioning |
|---|---|---|---|
Boehringer Ingelheim Animal Health | Multinational | Swine (PCV2, PRRS), poultry, companion | Global #3; animal health revenue USD 4.94 bn (2024, PharmaShots). Strong position in Korean swine biologics |
Zoetis | Multinational | All species | Global #1; revenue USD 9.25 bn (2024, PharmaShots) |
MSD Animal Health (Merck) | Multinational | Swine, poultry, companion; ASF vaccine development presented at IPVS 2026 | Global #2; revenue USD 5.87 bn (2024, PharmaShots) |
Elanco | Multinational | Companion, poultry. Also CAVAC's distribution partner in China | Competitor and partner |
Ceva Santé Animale | Multinational | Poultry vaccines, swine | — |
Komipharm (KOSDAQ) | Korean | ASF vaccine (Pro-Vac ASF, export licence 16 Apr 2026); PED vaccine (China approval Feb 2025) | Most direct domestic rival in ASF; first user of the APQA BL3 suite |
Daesung Microbiological Labs (대성미생물연구소, KOSDAQ) | Korean | Vaccines, antibiotics, feed additives (about 150 products) | Broader, lower-concentration portfolio; KVGMP plant expansion; exports 26% of revenue in its latest reported period |
Green Cross Veterinary Products (녹십자수의약품) | Korean | Swine and poultry vaccines; PCV technology tie-up with Optipharm (2023) | Domestic competitor in swine biologics |
Optipharm (KOSDAQ) | Korean | Diagnostics, vaccines; K-FMD partner | Partner in FMD; competitor in some swine vaccines |
Woogene B&G (우진비앤지, KOSDAQ) | Korean | Veterinary drugs, fish vaccines; goat CLA vaccine patent | Head-to-head in goat CLA from 2027 |
Eagle Vet (이글벳, KOSDAQ) | Korean | Veterinary drugs, pet food distribution | Overlaps mainly in companion-animal channels |
FVC (에프브이씨) | Korean | Domestic inactivated FMD vaccine (APQA technology transfer due by end-2026) | Competitor to the K-FMD programme |
Careside | Korean | ASF vaccine candidate (with Spain's CSIC) | ASF pipeline competitor |
AVAC Vietnam JSC; Navetco | Vietnamese | Licensed ASF live vaccines (AVAC licensed since Jul 2023) | Incumbents in the first ASF-X target market. WOAH raised concerns about data sharing for AVAC (Reuters via Tribune India) |
Peer Comparison FY2025
| Metric | CAVAC | Zoetis | MSD Animal Health | Boehringer Ingelheim AH |
|---|---|---|---|---|
Revenue | KRW 49.1 bn (FY2025), about USD 0.035 bn | USD 9.25 bn (2024) | USD 5.87 bn (2024) | USD 4.94 bn (2024) |
Revenue growth (%) | 7.6 (FY2025) | — | — | — |
Operating margin (%) | 13.2 (FY2025) | — | Not reported separately at segment level in sources reviewed | — |
R&D intensity (%) | 4.6 (SG&A-expensed, FY2025); management cites about 10% | — | — | — |



